EXPOSURE-RESPONSE CHARACTERISTICS AND PREDICTORS OF EFFICACY IN MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS PATIENTS RECEIVING TOFACITINIB.

被引：0
|
作者：
Hutmacher, M. M. [1 ]
Papp, K. A. [2 ]
Lebwohl, M. [3 ]
Ito, K. [4 ]
Tan, H. [4 ]
Wolk, R. [4 ]
Mebus, C. [4 ]
Rottinghaus, S. [4 ]
Valdez, H. [5 ]
Krishnaswami, S. [4 ]
Gupta, P. [4 ]
机构：
[1] Ann Arbor Pharmacometr Grp A2PG, Ann Arbor, MI USA
[2] Prob Med Res & K Papp Clin Res Inc, Waterloo, ON, Canada
[3] Icahn Sch Med Mt Sinai, Kimberly & Eric J Waldman Dept Dermatol, New York, NY 10029 USA
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, New York, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-082
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [41] Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without PsA.
    Menter, MA
    Gordon, KB
    Leonardi, C
    Heffernan, MP
    Chen, DM
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S611 - S612
  • [42] Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial
    Mukherjee, Arnab
    Hazra, Anasuya
    Smith, Mike K.
    Martin, Steven W.
    Mould, Diane R.
    Su, Chinyu
    Niezychowski, Wojciech
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (06) : 1136 - 1145
  • [43] Tofacitinib in patients with moderate to severe chronic plaque psoriasis: 2-year efficacy and safety in an open-label long-term extension study
    Paul, Carle
    Langley, Richard G.
    Valenzuela, Fernando
    Cather, Jennifer
    Gardner, Annie
    Proulx, James
    Tan, Huaming
    Wolk, Robert
    Kaur, Mandeep
    Rottinghaus, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB278 - AB278
  • [44] The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
    Zhang, JianZhong
    Tsai, Tsen-Fang
    Lee, Min-Geol
    Zheng, Min
    Wang, Gang
    Jin, HongZhong
    Gu, Jun
    Li, RuoYu
    Liu, QuanZhong
    Chen, Jin
    Tu, CaiXia
    Qi, ChunMei
    Zhu, Hua
    Ports, William C.
    Crook, Tim
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2017, 88 (01) : 36 - 45
  • [45] Efficacy and Safety of Ixekizumab in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis
    Paller, Amy
    Seyger, Marieke
    Alejandro Magarinos, Gabriel
    Bagel, Jerry
    Keller, Stuart
    Capriles, Claudia Rodriguez
    Gallo, Gaia
    Edson-Heredia, Emily
    Li, Lingnan
    Xu, Wen
    Papp, Kim
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 17 - 17
  • [46] Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis
    Tan, Huaming
    Valdez, Hernan
    Griffiths, Chris E. M.
    Mrowietz, Ulrich
    Tallman, Anna
    Wolk, Robert
    Gordon, Kenneth
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (01) : 3 - 7
  • [47] Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis
    Langley, Richard G.
    Kasichayanula, Sree
    Trivedi, Mona
    Aras, Girish A.
    Kaliyaperumal, Arunan
    Yuraszeck, Theresa
    Gibbs, John
    Gibbs, Megan
    Kricorian, Greg
    Paller, Amy S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (03): : 340 - 346
  • [48] IDENTIFYING PREDICTORS OF HIGH RESPONSE LEVELS IN IXEKIZUMAB-TREATED PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Reich, Kristian
    Eyerich, Kilian
    Costanzo, Antonio
    Lebwohl, Mark
    Garrelts, Alyssa
    Saure, Daniel
    Schuster, Christopher
    Blauvelt, Andrew
    Porsdal, Vibeke
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 46 - 46
  • [49] Identifying predictors of high response levels in ixekizumab-treated patients with moderate-to-severe plaque psoriasis
    Reich, Kristian
    Eyerich, Kilian
    Costanzo, Antonio
    Lebwohl, Mark
    Garrelts, Alyssa
    Saure, Daniel
    Schuster, Christopher
    Blauvelt, Andrew
    Truong, David
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 78 - 78
  • [50] Identifying predictors of high response levels in ixekizumab-treated patients with moderate-to-severe plaque psoriasis
    Reich, K.
    Eyerich, K.
    Costanzo, A.
    Lebwohl, M.
    Garrelts, A.
    Saure, D.
    Schuster, C.
    Blauvelt, A.
    Machacek, C.
    EXPERIMENTAL DERMATOLOGY, 2022, 31 (02) : E22 - E23
12345